Профилактика тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом: пресс-релиз о проведении Междисциплинарного совета экспертов

1. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310.

2. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279. doi: 10.1182/blood-2005-10-007252.

3. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–2400. doi: 10.1681/ASN.2006080811.

4. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol. 2011;3:5–12. doi: 10.2147/CPAA.S17904.

5. Ardissino G, Tel F, Testa S, et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis. 2014;63(4):652–655. doi: 10.1053/j.ajkd.2013.09.020.

6. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19): 1253–1258. doi: 10.1056/NEJM199511093331904.

7. Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–577. doi: 10.1016/S0140-6736(95)12360-1.

8. Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911–921. doi: 10.2147/TCRM.S3334.

9. McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–2345. doi: 10.2165/11208300-000000000-00000.

10. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12): 4123–4128. doi: 10.1182/blood-2007-06-095646.

11. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181– 192. doi: 10.1111/j.1365-2141.2007.06554.x.

12. Lee J, Jun Ho J, Sung Soo Y, et al. High prevalence and mortality associated with thromboembolism in Asian patients with paroxysmal noctu rnal hemоglobinuria (PNH). In: Haematologica. Supplement 2. 15th Congress of The European Hematology Association, Spain, Barcelona, June 10–13, 2010. Pavia: Societa italiana di ematologia; 2010. p. 205–206.

13. CDC. Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60:72–6.

14. www.gov.uk [Internet]. Public Health England. Immunisation of individuals with underlying medical conditions: the green book, chapter 7 [updated 2016 Sep 29; cited 2017 Jan 15]. Available from: https://www.gov.uk/government/publications/immunisation-of- individualswith-underlying-medical-conditions-the-green-book-chapter-7.

15. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521–540.

16. www.who.int [интернет]. Документ по позиции ВОЗ в отношении вакцинации против гемофильной инфекции типа b (Hib) — июль 2013 года. [WHO position paper on H. influenzae type b (Hib) Vaccination — July 2013] [доступ от 21.01.2017]. Доступ по ссылке http://www.who.int/immunization/Hib_Rus.pdf